Ritter Pharmaceuticals Inc (NASDAQ:RTTR)‘s stock had its “buy” rating reissued by equities researchers at Aegis in a report released on Tuesday.

RTTR has been the subject of a number of other reports. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 20th. Maxim Group reissued a “buy” rating on shares of Ritter Pharmaceuticals in a research report on Wednesday, June 22nd.

Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 22.99% during mid-day trading on Tuesday, hitting $2.30. The stock had a trading volume of 1,344,183 shares. The firm’s market capitalization is $19.74 million. Ritter Pharmaceuticals has a one year low of $0.98 and a one year high of $2.63. The stock’s 50 day moving average price is $1.57 and its 200 day moving average price is $1.54.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/ritter-pharmaceuticals-inc-rttr-rating-reiterated-by-aegis.html

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.14. Analysts forecast that Ritter Pharmaceuticals will post ($1.38) EPS for the current year.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

5 Day Chart for NASDAQ:RTTR

Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.